<DOC>
	<DOCNO>NCT02483533</DOCNO>
	<brief_summary>LIPO-202-CL-23 follow-on study evaluate post-treatment safety duration clinical effect LIPO-202 subject complete either LIPO-202-CL-18 LIPO-202-CL-19 ( parent study ) . No risk relate treatment anticipate subject receive additional treatment LIPO-202 Placebo LIPO-202 follow-on study .</brief_summary>
	<brief_title>Extension Study Evaluate Post-Treatment Safety Duration Clinical Effect LIPO-202</brief_title>
	<detailed_description />
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Healthy male nonpregnant female subject complete Study LIPO202CL18 LIPO202CL19 Capable provide write consent Willing comply study procedure schedule Female subject pregnant use adequate birth control method Plan start weight loss exercise program study Plan enroll another investigational drug device study Unlikely unable adhere study visit schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>